Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI3506 Administered as Single Ascending Doses in Healthy Adult Subjects, as Multiple Ascending Doses in COPD Subjects and Single Dose in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2019
At a glance
- Drugs MEDI-3506 (Primary) ; MEDI-3506 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors MedImmune
- 07 Jan 2019 Planned End Date changed from 19 Nov 2019 to 10 Sep 2019.
- 07 Jan 2019 Planned primary completion date changed from 19 Nov 2019 to 10 Sep 2019.
- 28 Nov 2018 Planned End Date changed from 24 Sep 2019 to 19 Nov 2019.